Treatment based on at least two reimbursed prescriptions within 3 months before and 1 year after the index date
| Patient characteristics | Matched RA comparisons | RA patients with ILD | ||
| n | % | n | % | |
| n | 9550 | 100.0 | 554 | 100.0 |
| Corticosteroid | ||||
| No | 7147 | 74.8 | 260 | 46.9 |
| Yes | 2403 | 25.2 | 294 | 53.1 |
| Methotrexate oral* | ||||
| No | 5976 | 62.6 | 421 | 76.0 |
| Yes | 3574 | 37.4 | 133 | 24.0 |
| Salazopyrin | ||||
| No | 8170 | 85.5 | 458 | 82.7 |
| Yes | 1380 | 14.5 | 96 | 17.3 |
| Azathioprin | ||||
| No | 9458 | 99.0 | 513 | 92.6 |
| Yes | 92 | 1.0 | 41 | 7.4 |
| Hydroxychloroquin | ||||
| No | 9002 | 94.3 | 508 | 91.7 |
| Yes | 548 | 5.7 | 46 | 8.3 |
Index date: the date when both the RA and ILD diagnosis have been assigned for RA patients with ILD and the matching date for the matched RA cohort.
*Information about hospital dispensed therapies; for example, subcutaneous methotrexate and biological therapies for RA are not available.
ILD, interstitial lung disease; RA, rheumatoid arthritis.